Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance

Reuters

2025/11/07

Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance

Sight Sciences Inc. reported third quarter 2025 total revenue of $19.9 million, a decrease of 1.0% compared to the same period in the prior year. The company's Surgical Glaucoma revenue increased 6.0%, while revenue from the Dry Eye segment declined 88.0% compared to the third quarter of 2024, due to a continued focus on achieving reimbursed market access. Net loss for the quarter was $8.2 million, or $0.16 per share, compared to a net loss of $11.1 million, or $0.22 per share, in the prior year period. Total operating expenses were reduced to $25.1 million, down 11.0% year-over-year, including $2.8 million in restructuring costs. Sight Sciences raised its full year 2025 revenue guidance to $76.0 million to $78.0 million, now expecting a 2.0% to 5.0% decline compared to 2024 revenue. Cash and cash equivalents totaled $92.4 million as of September 30, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-269525), on November 06, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581787048"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581787048\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581787048?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581787048","market":"us","top_or_hot":-1,"title":"Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sight Sciences Inc. reported third quarter 2025 total revenue of $19.9 million, a decrease of 1.0% compared to the same period in the prior year. The company's Surgical Glaucoma revenue increased 6.0%, while revenue from the Dry Eye segment declined 88.0% compared to the third quarter of 2024, due to a continued focus on achieving reimbursed market access. Net loss for the quarter was $8.2 million, or $0.16 per share, compared to a net loss of $11.1 million, or $0.22 per share, in the prior year period. Total operating expenses were reduced to $25.1 million, down 11.0% year-over-year, including $2.8 million in restructuring costs. Sight Sciences raised its full year 2025 revenue guidance to $76.0 million to $78.0 million, now expecting a 2.0% to 5.0% decline compared to 2024 revenue. Cash and cash equivalents totaled $92.4 million as of September 30, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-269525), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 05:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sight Sciences Inc. reported third quarter 2025 total revenue of $19.9 million, a decrease of 1.0% compared to the same period in the prior year. The company's Surgical Glaucoma revenue increased 6.0%, while revenue from the Dry Eye segment declined 88.0% compared to the third quarter of 2024, due to a continued focus on achieving reimbursed market access. Net loss for the quarter was $8.2 million, or $0.16 per share, compared to a net loss of $11.1 million, or $0.22 per share, in the prior year period. Total operating expenses were reduced to $25.1 million, down 11.0% year-over-year, including $2.8 million in restructuring costs. Sight Sciences raised its full year 2025 revenue guidance to $76.0 million to $78.0 million, now expecting a 2.0% to 5.0% decline compared to 2024 revenue. Cash and cash equivalents totaled $92.4 million as of September 30, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-269525), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"半新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1Fnfd4:1","article_id":"2581787048","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581787048","pubTimestamp":1762464249,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sight Sciences Inc. reported third quarter 2025 total revenue of $19.9 million, a decrease of 1.0% compared to the same period in the prior year. The company's Surgical Glaucoma revenue increased 6.0%, while revenue from the Dry Eye segment declined 88.0% compared to the third quarter of 2024, due to a continued focus on achieving reimbursed market access. Net loss for the quarter was $8.2 million, or $0.16 per share, compared to a net loss of $11.1 million, or $0.22 per share, in the prior year period. Total operating expenses were reduced to $25.1 million, down 11.0% year-over-year, including $2.8 million in restructuring costs. Sight Sciences raised its full year 2025 revenue guidance to $76.0 million to $78.0 million, now expecting a 2.0% to 5.0% decline compared to 2024 revenue. Cash and cash equivalents totaled $92.4 million as of September 30, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4082":"医疗保健设备","SGHT":"Sight Sciences, Inc."},"translate_title":"Sight Sciences公布第三季度净亏损820万美元，营收1990万美元，并上调2025年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGHT":0.9},"content_text":"Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance\n    \n\n        Sight Sciences Inc. reported third quarter 2025 total revenue of $19.9 million, a decrease of 1.0% compared to the same period in the prior year. The company's Surgical Glaucoma revenue increased 6.0%, while revenue from the Dry Eye segment declined 88.0% compared to the third quarter of 2024, due to a continued focus on achieving reimbursed market access. Net loss for the quarter was $8.2 million, or $0.16 per share, compared to a net loss of $11.1 million, or $0.22 per share, in the prior year period. Total operating expenses were reduced to $25.1 million, down 11.0% year-over-year, including $2.8 million in restructuring costs. Sight Sciences raised its full year 2025 revenue guidance to $76.0 million to $78.0 million, now expecting a 2.0% to 5.0% decline compared to 2024 revenue. Cash and cash equivalents totaled $92.4 million as of September 30, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-269525), on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}